Valneva SE Sponsored ADR (NASDAQ:VALN) Given Average Rating of “Hold” by Analysts

Posted by Brenda Bartman on Jul 31st, 2026

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN – Get Free Report) have earned an average recommendation of “Hold” from the five research firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $11.9750.

Several research analysts recently issued reports on VALN shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valneva in a research report on Thursday, June 18th. The Goldman Sachs Group lowered Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target for the company. in a research note on Wednesday, April 22nd. Guggenheim set a $11.00 price objective on Valneva in a report on Thursday, April 16th. Finally, Wall Street Zen upgraded Valneva from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st.

Read Our Latest Stock Analysis on Valneva

Valneva Trading Down 0.0%

Shares of Valneva stock opened at $5.07 on Friday. The company has a debt-to-equity ratio of 2.14, a current ratio of 2.14 and a quick ratio of 1.60. Valneva has a 1 year low of $4.75 and a 1 year high of $12.25. The firm has a market cap of $480.90 million, a PE ratio of -2.71 and a beta of 1.77. The company has a 50 day simple moving average of $5.34 and a two-hundred day simple moving average of $7.25.

Valneva (NASDAQ:VALN – Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.42) EPS for the quarter. The company had revenue of $35.77 million during the quarter. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%. Analysts expect that Valneva will post -1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. purchased a new position in shares of Valneva during the fourth quarter worth approximately $44,000. JPMorgan Chase & Co. purchased a new stake in shares of Valneva in the 3rd quarter valued at $124,000. XTX Topco Ltd purchased a new stake in shares of Valneva in the 4th quarter valued at $94,000. Finally, Marex Group plc bought a new position in shares of Valneva during the 2nd quarter valued at $64,000. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

(Get Free Report)

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.